Iranian Journal of Radiology

Published by: Kowsar

Ocular Biodistribution of 89Zr-Bevacizumab in New Zealand Rabbits Determined Using PET/MRI: A Feasibility Study

Xiaoyuan Liu 1 , Jianqiang Ye 2 , Yan Zhang 3 , Quan Liu 4 , Ruizhen Bai 1 , Wenbo Yuan 1 , Dongyan Cai 4 , Xiaoyuan Zheng 1 , Yun Bian 1 , Shijun Zhou 1 , Juan Lv 1 , Yongjuan Ding 1 , Fen Xie 1 , Hongwen Lu 1 and Bingxue Xie 1 , 3 , *
Authors Information
1 Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China
2 Department of Pathology, Wuxi Huishan District People’s Hospital, Wuxi, China
3 Department of Pharmacy, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, Jiangsu, China
4 Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
Article information
  • Iranian Journal of Radiology: 16 (2); e68697
  • Published Online: January 23, 2019
  • Article Type: Research Article
  • Received: March 16, 2018
  • Revised: December 12, 2018
  • Accepted: December 18, 2018
  • DOI: 10.5812/iranjradiol.68697

To Cite: Liu X, Ye J, Zhang Y, Liu Q, Bai R, et al. Ocular Biodistribution of 89Zr-Bevacizumab in New Zealand Rabbits Determined Using PET/MRI: A Feasibility Study, Iran J Radiol. Online ahead of Print ; 16(2):e68697. doi: 10.5812/iranjradiol.68697.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Bashir U, Mallia A, Stirling J, Joemon J, MacKewn J, Charles-Edwards G, et al. PET/MRI in oncological imaging: State of the art. Diagnostics (Basel). 2015;5(3):333-57. doi: 10.3390/diagnostics5030333. [PubMed: 26854157]. [PubMed Central: PMC4665605].
  • 2. Garibotto V, Heinzer S, Vulliemoz S, Guignard R, Wissmeyer M, Seeck M, et al. Clinical applications of hybrid PET/MRI in neuroimaging. Clin Nucl Med. 2013;38(1):e13-8. doi: 10.1097/RLU.0b013e3182638ea6. [PubMed: 23242058].
  • 3. Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, et al. Usefulness of integrated PET/MRI in head and neck cancer: a preliminary study. Nucl Med Mol Imaging. 2014;48(2):98-105. doi: 10.1007/s13139-013-0252-2. [PubMed: 24900149]. [PubMed Central: PMC4028474].
  • 4. Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Hell J Nucl Med. 2016;19(3):254-68. doi: 10.1967/s002449910409. [PubMed: 27824966].
  • 5. Aras M, Ones T, Dane F, Nosheri O, Inanir S, Erdil TY, et al. False positive FDG PET/CT resulting from fibrous dysplasia of the bone in the work-up of a patient with bladder cancer: case report and review of the literature. Iran J Radiol. 2012;10(1):41-4. doi: 10.5812/iranjradiol.10303. [PubMed: 23599713]. [PubMed Central: PMC3618905].
  • 6. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331-71. doi: 10.1016/j.preteyeres.2008.05.001. [PubMed: 18653375]. [PubMed Central: PMC3682685].
  • 7. Ajlan RS, Silva PS, Sun JK. Vascular endothelial growth factor and diabetic retinal disease. Semin Ophthalmol. 2016;31(1-2):40-8. doi: 10.3109/08820538.2015.1114833. [PubMed: 26959128].
  • 8. Marneros AG. Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. EMBO Mol Med. 2016;8(3):208-31. doi: 10.15252/emmm.201505613. [PubMed: 26912740]. [PubMed Central: PMC4772957].
  • 9. Kovach JL, Schwartz SG, Flynn HW Jr, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012:786870. doi: 10.1155/2012/786870. [PubMed: 22523653]. [PubMed Central: PMC3317200].
  • 10. Mirabelli P, Peebo BB, Xeroudaki M, Koulikovska M, Lagali N. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. Exp Eye Res. 2014;125:118-27. doi: 10.1016/j.exer.2014.06.006. [PubMed: 24933712].
  • 11. Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54(7):1014-8. doi: 10.2967/jnumed.112.117218. [PubMed: 23651946].
  • 12. Gaykema SB, Schroder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20(15):3945-54. doi: 10.1158/1078-0432.CCR-14-0491. [PubMed: 25085789].
  • 13. Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2015;56(1):63-9. doi: 10.2967/jnumed.114.144840. [PubMed: 25476536].
  • 14. van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, et al. Everolimus reduces (89)Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med. 2014;55(7):1087-92. doi: 10.2967/jnumed.113.129056. [PubMed: 24790218].
  • 15. van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schroder CP, Pot L, Kosterink JG, et al. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res. 2012;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. [PubMed: 23014526].
  • 16. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010;51(5):761-7. doi: 10.2967/jnumed.109.071043. [PubMed: 20395337].
  • 17. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-7. doi: 10.1056/NEJM199412013312203. [PubMed: 7526212].
  • 18. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463-7. doi: 10.1074/jbc.274.33.23463. [PubMed: 10438525].
  • 19. Gamulescu MA, Radeck V, Lustinger B, Fink B, Helbig H. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol. 2010;30(3):261-6. doi: 10.1007/s10792-009-9318-7. [PubMed: 19633973].
  • 20. Schmucker C, Antes G, Lelgemann M. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248(3):451-2. author reply 453-4. doi: 10.1007/s00417-009-1249-5. [PubMed: 20012081].
  • 21. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008-15. doi: 10.1016/j.ophtha.2014.12.017. [PubMed: 25687024]. [PubMed Central: PMC4414677].
  • 22. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK; Diabetic Retinopathy Clinical Research Network, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-7. doi: 10.1016/j.ophtha.2007.05.062. [PubMed: 17698196]. [PubMed Central: PMC2245885].
  • 23. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology. 2010;117(6):1078-1086 e2. doi: 10.1016/j.ophtha.2010.03.045. [PubMed: 20416952].
  • 24. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology. 2014;121(12):2473-81. doi: 10.1016/j.ophtha.2014.07.002. [PubMed: 25155371].
  • 25. Dorta P, Kychenthal A. Spectral-domain optical coherence tomography of the macula in preterm infants treated with bevacizumab for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2015;46(3):321-6. doi: 10.3928/23258160-20150323-04. [PubMed: 25856817].
  • 26. Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between ranibizumab and bevacizumab. Retina. 2015;35(4):667-74. doi: 10.1097/IAE.0000000000000380. [PubMed: 25462435].
  • 27. Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956-61. doi: 10.1167/iovs.14-15842. [PubMed: 25613938].
  • 28. Ye Z, Ji YL, Ma X, Wen JG, Wei W, Huang SM. Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. Int J Ophthalmol. 2015;8(4):653-8. doi: 10.3980/j.issn.2222-3959.2015.04.02. [PubMed: 26309857]. [PubMed Central: PMC4539635].
  • 29. Jang BS. MicroSPECT and MicroPET imaging of small animals for drug development. Toxicol Res. 2013;29(1):1-6. doi: 10.5487/TR.2013.29.1.001. [PubMed: 24278622]. [PubMed Central: PMC3834443].
  • 30. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48(8):1313-9. doi: 10.2967/jnumed.107.041301. [PubMed: 17631557].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments